Core Insights - Veeva Systems is launching Veeva AI, a generative AI layer integrated into its Vault platform to enhance automation and efficiency for life sciences companies [1][6] - The integration of AI aims to improve productivity and decision-making in clinical, quality, and regulatory functions, thereby increasing customer reliance on Veeva's software [2][6] - Veeva is experiencing steady financial performance and geographic expansion, particularly in China, positioning itself as a key technology provider as life sciences firms adopt AI [2] Competitive Landscape - IQVIA Holdings is also investing in AI, utilizing its Orchestrated Clinical Trials platform to enhance trial planning and patient recruitment, showcasing a different approach by combining data, analytics, and services [3] - Schrodinger Inc. is leveraging AI in drug discovery, focusing on deep learning and molecular simulation to optimize drug compounds, thus complementing Veeva's offerings in the life sciences ecosystem [4] Financial Performance - Veeva's shares have increased by 34.6% year-to-date, outperforming the industry growth of 22.5% [5][6] - The company has a forward price-to-sales ratio of 14.25, which is above the industry average, indicating a premium valuation [8] - The Zacks Consensus Estimate predicts a 15.8% rise in Veeva's fiscal 2026 earnings compared to the previous year [9]